Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/19406 |
Resumo: | Malignant neoplasms represents a group of diseases that features, as a characteristic, the genetic differentiation of the original tissue, leading to the disordered growth of cells, invading normal tissues and organs. Among the most aggressive tumors, Glioblastoma Multiforme has a mortality rate around 95% and survival’s average of 15 months, even though all treatment available. Temozolomide (TMZ) is the chemotherapeutic drug so far tested and approved with the highest response in this tumor sub-type and must be associated to other treatments to achieve better results. Thus, the purpose of this work was to evaluate the performance of this therapeutic modality with gold nanoparticles (AuNPs) and also combined with radiotherapy. TMZ hydrolysis was characterized at different pH and the chemical changes on molecular structure was determined via Fourier Transform Infrared Spectroscopy (FT-IR). The treatment performance was verified in vitro test using TMZ, TMZ plus AuNPs and associated with radiotherapy. The TMZ concentrations were varied from 0 (control group) to 1000µM, combined with AuNPs from 0 (control group) to10¹⁰ nanoparticles per well. The results showed the drug is stable at pH values between 2 to 4, but for pH values close to the physiological or basic medium, degradation is accentuated reaching a rate of 16 %/hour. The changes on molecular structure of TMZ can be observed through the FT-IR spectra, where the release of oxygen in the structure has influence on C=O group. The results of in vitro experiments showed that the highest poor results in the absence of ionizing irradiation. However, for experiments with TMZ and nanoparticles associated to radiotherapy, the performance of the treatment increased. In summary, the AuNPs showed important results under irradiation, revealing the same level of cytotoxicity for the highest TMZ concentration without irradiation. Also, the synergic effect between AuNPs and TMZ was observed under irradiation condition. |
id |
UNIFEI_fe4c0a14450e18bb45e38b3a12a9c65c |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/19406 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme TreatmentNanopartículas de oro asociadas con temozolomida para el tratamiento del Glioblastoma MultiformeNanopartículas de ouro associadas à temozolomida para tratamento de Glioblastoma MultiformeGlioblastomaGold nanoparticlesTemozolomideRadiotherapy.GlioblastomaNanopartículas de oroTemozolomidaRadioterapia.GlioblastomaNanopartículas de ouroTemozolomidaRadioterapia.Malignant neoplasms represents a group of diseases that features, as a characteristic, the genetic differentiation of the original tissue, leading to the disordered growth of cells, invading normal tissues and organs. Among the most aggressive tumors, Glioblastoma Multiforme has a mortality rate around 95% and survival’s average of 15 months, even though all treatment available. Temozolomide (TMZ) is the chemotherapeutic drug so far tested and approved with the highest response in this tumor sub-type and must be associated to other treatments to achieve better results. Thus, the purpose of this work was to evaluate the performance of this therapeutic modality with gold nanoparticles (AuNPs) and also combined with radiotherapy. TMZ hydrolysis was characterized at different pH and the chemical changes on molecular structure was determined via Fourier Transform Infrared Spectroscopy (FT-IR). The treatment performance was verified in vitro test using TMZ, TMZ plus AuNPs and associated with radiotherapy. The TMZ concentrations were varied from 0 (control group) to 1000µM, combined with AuNPs from 0 (control group) to10¹⁰ nanoparticles per well. The results showed the drug is stable at pH values between 2 to 4, but for pH values close to the physiological or basic medium, degradation is accentuated reaching a rate of 16 %/hour. The changes on molecular structure of TMZ can be observed through the FT-IR spectra, where the release of oxygen in the structure has influence on C=O group. The results of in vitro experiments showed that the highest poor results in the absence of ionizing irradiation. However, for experiments with TMZ and nanoparticles associated to radiotherapy, the performance of the treatment increased. In summary, the AuNPs showed important results under irradiation, revealing the same level of cytotoxicity for the highest TMZ concentration without irradiation. Also, the synergic effect between AuNPs and TMZ was observed under irradiation condition.Las neoplasias malignas representan un grupo de enfermedades que tiene como característica la diferenciación genética del tejido original, lo que lleva al crecimiento desordenado de las células, invadiendo tejidos y órganos normales. Entre los tumores más agresivos, el glioblastoma multiforme tiene una tasa de mortalidad de alrededor del 95% y un promedio de supervivencia de 15 meses, a pesar de que todos los tratamientos están disponibles. La temozolomida (TMZ) es el fármaco quimioterapéutico probado y aprobado hasta ahora con mayor respuesta en este subtipo de tumor y debe asociarse a otros tratamientos para lograr mejores resultados. Así, el propósito de este trabajo fue evaluar el desempeño de esta modalidad terapéutica con nanopartículas de oro (AuNPs) y también combinado con radioterapia. Se caracterizó la hidrólisis de TMZ a diferentes pH y se determinaron los cambios químicos en la estructura molecular mediante Espectroscopía Infrarroja por Transformada de Fourier (FT-IR). El desempeño del tratamiento fue verificado in vitro usando TMZ, TMZ más AuNPs y asociado a radioterapia. Las concentraciones de TMZ se variaron de 0 (grupo de control) a 1000 µM, combinadas con AuNP de 0 (grupo de control) a 10¹⁰ nanopartículas por pocillo. El fármaco es estable a valores de pH entre 2 a 4, pero para valores de pH cercanos al medio fisiológico o básico, la degradación se acentúa alcanzando una tasa de 16% / hora. Los cambios en la estructura molecular de TMZ se pueden observar a través de los espectros FT-IR, donde la liberación de oxígeno en la estructura tiene influencia sobre el grupo C=O. Los resultados de los experimentos in vitro mostraron que los peores resultados se produjeron en ausencia de irradiación ionizante. Sin embargo, para los experimentos con TMZ y nanopartículas asociadas a la radioterapia, el rendimiento del tratamiento aumentó. Las AuNP mostraron resultados importantes bajo irradiación, revelando el mismo nivel de citotoxicidad para la concentración más alta de TMZ sin irradiación. Además, el efecto sinérgico entre AuNP y TMZ se observó en condiciones de irradiación.As neoplasias malignas representam um grupo de doenças que apresenta, como característica, a diferenciação genética do tecido original, levando ao crescimento desordenado das células, invadindo tecidos e órgãos normais. Dentre os tumores mais agressivos, o Glioblastoma Multiforme tem mortalidade em torno de 95% e sobrevida média de 15 meses, mesmo com todos os tratamentos disponíveis. A temozolomida (TMZ) é o quimioterápico até o momento testado e aprovado com maior resposta nesse subtipo tumoral e deve ser associado a outros tratamentos para obter melhores resultados. Assim, o objetivo deste trabalho foi avaliar o desempenho desta modalidade terapêutica com nanopartículas de ouro (AuNPs) e também combinada com a radioterapia. A hidrólise de TMZ foi caracterizada em diferentes pH e as alterações químicas na estrutura molecular foram determinadas por meio de Espectroscopia de Infravermelho com Transformada de Fourier (FT-IR). O desempenho do tratamento foi verificado em teste in vitro utilizando TMZ, TMZ mais AuNPs e associado à radioterapia. As concentrações de TMZ variaram de 0 (grupo de controle) a 1000 µM, combinadas com AuNPs de 0 (grupo de controle) a 10¹⁰ nanopartículas por poço. Os resultados mostraram que o fármaco é estável em valores de pH entre 2 a 4, mas para valores de pH próximos ao meio fisiológico ou básico, a degradação é acentuada atingindo uma taxa de 16% / hora. As mudanças na estrutura molecular da TMZ podem ser observadas através dos espectros FT-IR, quando a liberação de oxigênio na estrutura influencia no grupo C=O. Os resultados dos experimentos in vitro mostraram que os piores resultados foram na ausência de irradiação ionizante. Porém, para experimentos com TMZ e nanopartículas associadas à radioterapia, o desempenho do tratamento aumentou. A Conclusão foi que as AuNPs apresentaram resultados importantes sob irradiação, revelando o mesmo nível de citotoxicidade para a maior concentração de TMZ sem irradiação. Além disso, o efeito sinérgico entre AuNPs e TMZ foi observado sob condição de irradiação.Research, Society and Development2021-08-25info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1940610.33448/rsd-v10i11.19406Research, Society and Development; Vol. 10 No. 11; e146101119406Research, Society and Development; Vol. 10 Núm. 11; e146101119406Research, Society and Development; v. 10 n. 11; e1461011194062525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/19406/17352Copyright (c) 2021 Vanessa Dias Gialluca; Vitor Gabriel Poli de Lima; Aloísio Caixeta; Maiara Lima Castilho; Leandro José Ranierohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessGialluca, Vanessa Dias Lima, Vitor Gabriel Poli de Caixeta, AloísioCastilho, Maiara Lima Raniero, Leandro José 2021-10-23T19:01:11Zoai:ojs.pkp.sfu.ca:article/19406Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:18.473716Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment Nanopartículas de oro asociadas con temozolomida para el tratamiento del Glioblastoma Multiforme Nanopartículas de ouro associadas à temozolomida para tratamento de Glioblastoma Multiforme |
title |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment |
spellingShingle |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment Gialluca, Vanessa Dias Glioblastoma Gold nanoparticles Temozolomide Radiotherapy. Glioblastoma Nanopartículas de oro Temozolomida Radioterapia. Glioblastoma Nanopartículas de ouro Temozolomida Radioterapia. |
title_short |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment |
title_full |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment |
title_fullStr |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment |
title_full_unstemmed |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment |
title_sort |
Gold nanoparticles associated with temozolomide for glioblastoma Multiforme Treatment |
author |
Gialluca, Vanessa Dias |
author_facet |
Gialluca, Vanessa Dias Lima, Vitor Gabriel Poli de Caixeta, Aloísio Castilho, Maiara Lima Raniero, Leandro José |
author_role |
author |
author2 |
Lima, Vitor Gabriel Poli de Caixeta, Aloísio Castilho, Maiara Lima Raniero, Leandro José |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Gialluca, Vanessa Dias Lima, Vitor Gabriel Poli de Caixeta, Aloísio Castilho, Maiara Lima Raniero, Leandro José |
dc.subject.por.fl_str_mv |
Glioblastoma Gold nanoparticles Temozolomide Radiotherapy. Glioblastoma Nanopartículas de oro Temozolomida Radioterapia. Glioblastoma Nanopartículas de ouro Temozolomida Radioterapia. |
topic |
Glioblastoma Gold nanoparticles Temozolomide Radiotherapy. Glioblastoma Nanopartículas de oro Temozolomida Radioterapia. Glioblastoma Nanopartículas de ouro Temozolomida Radioterapia. |
description |
Malignant neoplasms represents a group of diseases that features, as a characteristic, the genetic differentiation of the original tissue, leading to the disordered growth of cells, invading normal tissues and organs. Among the most aggressive tumors, Glioblastoma Multiforme has a mortality rate around 95% and survival’s average of 15 months, even though all treatment available. Temozolomide (TMZ) is the chemotherapeutic drug so far tested and approved with the highest response in this tumor sub-type and must be associated to other treatments to achieve better results. Thus, the purpose of this work was to evaluate the performance of this therapeutic modality with gold nanoparticles (AuNPs) and also combined with radiotherapy. TMZ hydrolysis was characterized at different pH and the chemical changes on molecular structure was determined via Fourier Transform Infrared Spectroscopy (FT-IR). The treatment performance was verified in vitro test using TMZ, TMZ plus AuNPs and associated with radiotherapy. The TMZ concentrations were varied from 0 (control group) to 1000µM, combined with AuNPs from 0 (control group) to10¹⁰ nanoparticles per well. The results showed the drug is stable at pH values between 2 to 4, but for pH values close to the physiological or basic medium, degradation is accentuated reaching a rate of 16 %/hour. The changes on molecular structure of TMZ can be observed through the FT-IR spectra, where the release of oxygen in the structure has influence on C=O group. The results of in vitro experiments showed that the highest poor results in the absence of ionizing irradiation. However, for experiments with TMZ and nanoparticles associated to radiotherapy, the performance of the treatment increased. In summary, the AuNPs showed important results under irradiation, revealing the same level of cytotoxicity for the highest TMZ concentration without irradiation. Also, the synergic effect between AuNPs and TMZ was observed under irradiation condition. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-08-25 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19406 10.33448/rsd-v10i11.19406 |
url |
https://rsdjournal.org/index.php/rsd/article/view/19406 |
identifier_str_mv |
10.33448/rsd-v10i11.19406 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19406/17352 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 11; e146101119406 Research, Society and Development; Vol. 10 Núm. 11; e146101119406 Research, Society and Development; v. 10 n. 11; e146101119406 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052808213561344 |